Maxigen Biotech Inc (1783) - Total Liabilities
Based on the latest financial reports, Maxigen Biotech Inc (1783) has total liabilities worth NT$364.27 Million TWD (≈ $11.48 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Maxigen Biotech Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how Maxigen Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See Maxigen Biotech Inc (1783) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Maxigen Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Maxigen Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dong Yang Pipe
KO:008970
|
Korea | ₩98.08 Billion |
|
Icon Group
TA:ICON
|
Israel | ILA364.43 Million |
|
Amica S.A.
WAR:AMC
|
Poland | zł930.90 Million |
|
Bajaj Healthcare Limited
NSE:BAJAJHCARE
|
India | Rs3.90 Billion |
|
Nicola Mining Inc
V:NIM
|
Canada | CA$17.60 Million |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
Brazil | R$14.38 Billion |
|
Idsud S.A
PA:ALIDS
|
France | €8.95 Million |
|
Coya Therapeutics, Inc. Common Stock
NASDAQ:COYA
|
USA | $4.30 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Maxigen Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Maxigen Biotech Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maxigen Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maxigen Biotech Inc (2009–2025)
The table below shows the annual total liabilities of Maxigen Biotech Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$355.54 Million ≈ $11.20 Million |
+71.46% |
| 2024-12-31 | NT$207.36 Million ≈ $6.53 Million |
+57.23% |
| 2023-12-31 | NT$131.88 Million ≈ $4.16 Million |
-13.27% |
| 2022-12-31 | NT$152.07 Million ≈ $4.79 Million |
+23.16% |
| 2021-12-31 | NT$123.47 Million ≈ $3.89 Million |
+28.29% |
| 2020-12-31 | NT$96.24 Million ≈ $3.03 Million |
-71.20% |
| 2019-12-31 | NT$334.17 Million ≈ $10.53 Million |
+14.25% |
| 2018-12-31 | NT$292.48 Million ≈ $9.21 Million |
-4.96% |
| 2017-12-31 | NT$307.73 Million ≈ $9.70 Million |
-2.63% |
| 2016-12-31 | NT$316.04 Million ≈ $9.96 Million |
-6.60% |
| 2015-12-31 | NT$338.38 Million ≈ $10.66 Million |
+147.62% |
| 2014-12-31 | NT$136.65 Million ≈ $4.31 Million |
+8.42% |
| 2013-12-31 | NT$126.04 Million ≈ $3.97 Million |
+4.94% |
| 2012-12-31 | NT$120.10 Million ≈ $3.78 Million |
+2.30% |
| 2011-12-31 | NT$117.40 Million ≈ $3.70 Million |
+241.60% |
| 2010-12-31 | NT$34.37 Million ≈ $1.08 Million |
+12.63% |
| 2009-12-31 | NT$30.51 Million ≈ $961.36K |
-- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more